# Glatiramer acetate

Approved MS drug made of random myelin-mimicking peptide chains; modest relapse cut, injection burden.

- Page: https://peprank.xyz/peptides/glatiramer-acetate
- Category: Neuroprotection & repair (Research peptide)
- Also known as: Copaxone; Glatopa (generic); copolymer 1 / Cop-1; GA
- Routes: Injection
- Safety tier: Strict: Avoid · Balanced: Avoid · Evidence only: Avoid
- Risk axes (0 none to 3 severe): Seen harm 3, Mechanism 2, Data gap 0, Silent harm 2, Product 0
- Positive: 37% of 24 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #59 of 61 research peptides
- Graded reports: 24 (Glowing 2, Positive 6, Mixed 4, Nothing 2, Negative 4, Bad reaction 6)
- Evidence: Approved drug — FDA-approved for relapsing MS since 1996, EU and worldwide; several placebo-controlled RCTs (n up to 1,404). No benefit on progression in primary progressive MS (PROMiSe, n=943). Remyelination evidence is animal only.
- Access: Approved drug
- Onset: Relapse reduction builds over months; the trials measured it at one to two years. Nothing is felt from a dose except site reactions.
- Lasts: Continuous treatment; the effect lasts only while it is taken.
- Cost per month: Usually covered by insurance or national health systems; a specialty-drug price in the US (thousands of dollars a month at list), far less in Europe and as generics.
- Updated: 2026-10-30

**Why Avoid under the strict bar:** Prescription immunomodulator for relapsing MS with an FDA boxed warning for anaphylaxis (82 cases, 6 deaths reported to 2024, some years into treatment), plus label warnings for liver injury and skin necrosis. Worth it for MS under a neurologist; not a self-directed peptide.

## What users report

Split. Long-term users (10-29 years) credit it with stable MRIs and staying mobile, and value its lack of immunosuppression, which also makes it the usual choice around pregnancy and breastfeeding. Against that: near-universal injection-site pain, welts and lumps, permanent fat loss (lipoatrophy) and in some cases skin necrosis; frightening immediate post-injection reactions (chest tightness, flushing, palpitations, 'what I imagine death feels like'), sometimes first appearing after years; and several first-hand anaphylaxis reports needing the ER and epinephrine. Reaction threads were searched on purpose, so bad reactions are over-represented in these 24 reports. Current community and specialist consensus favours starting on higher-efficacy drugs (anti-CD20s) instead. Felt nothing: Two of 24 reports describe new lesions or relapses with no benefit; r/MultipleSclerosis regulars widely call it the least effective DMT..

**Effects:** fewer relapses (about 30% fewer than placebo in trials); fewer new MRI lesions; not broadly immunosuppressive; usable in pregnancy and breastfeeding

**Downsides:** injection-site pain, welts, lumps and bruising; permanent lipoatrophy (dents) at injection sites; immediate post-injection reaction (flushing, chest pain, palpitations, breathlessness; about 16% on the daily dose); transient chest pain unrelated to injections; daily or three-times-weekly self-injection

**Risks:** Anaphylaxis, including fatal, at any point in treatment (FDA boxed warning, January 2025: 82 worldwide cases, 6 deaths); Hepatic injury including liver failure and hepatitis with jaundice, days to years after starting (label warning); Injection-site skin necrosis (postmarketing); Immune modulation; antibodies to the drug form in most patients (label precaution)

**Caveat:** Among MS drugs it is one of the lowest-efficacy options, and specialists now often start with high-efficacy drugs; its place today is mainly where its safety profile matters (pregnancy, breastfeeding, people who want to avoid immunosuppression). Remyelination or 'repair' is shown only in mice. Generic and brand versions are interchangeable in the US; some users report more reactions after switching, which has not been shown.

**Typical use:** 20 mg subq daily, or 40 mg subq three times a week at least 48 hours apart (the doses are not interchangeable).

**Getting it:** Prescription only, from a neurologist, via specialty pharmacy (Copaxone, the generic Glatopa and other generics). Not sold by research-peptide vendors.

**Stacked with:** Vitamin D (Commonly taken alongside by MS patients on any disease-modifying drug.); Benadryl and Tylenol before injecting (Some users pre-medicate to blunt post-injection reactions; this does not prevent anaphylaxis.)

## Risk profile

- **Seen harm 3/3:** The FDA attributes 82 worldwide anaphylaxis cases (1996 to May 2024) to glatiramer acetate, all needing emergency care or hospitalisation and six fatal, and added a boxed warning in January 2025; the label also warns of hepatic injury including liver failure and of injection-site skin necrosis. First-hand Reddit reports of ER-treated anaphylaxis match.
- **Mechanism 2/3:** An antigenic random polymer that deliberately modulates the immune response: drug-reactive IgG antibodies form in most patients, IgG rose to 3x baseline in 80% within 3 months, immune-complex deposition in kidneys was seen in rats and monkeys, and the label flags possible effects on tumour surveillance and infection defences without evidence of either. That is the immune-activation category, not a demonstrated in-vivo oncogenic or organ-damage pathway.
- **Data gap 0/3:** FDA-approved since 1996 with placebo-controlled RCTs including 251, 943 and 1,404 patients, a Cochrane review, a pregnancy database and nearly 30 years of post-marketing use (about 240,000 US prescriptions in 2023).
- **Silent harm 2/3:** Anaphylaxis itself is immediate and obvious (alone it would be a 1, since it can first appear years into treatment), but the label's hepatic injury can develop days to years after starting and shows on liver tests before it is felt, and lipoatrophy builds slowly and is permanent.
- **Product 0/3:** Bought only as a manufactured, regulated prescription product (Copaxone, Glatopa or other generics) from specialty pharmacies, self-injected subq from prefilled syringes; no grey-market or compounded supply. Product risk is technique (hitting a vessel, poor site rotation), not purity or sterility.
- **Never if:** Known hypersensitivity to glatiramer acetate or mannitol (label); Any previous anaphylaxis on glatiramer acetate, unless another clear cause is identified (boxed warning); Primary progressive MS as the reason for use (no benefit in the PROMiSe trial)

## Top reports

- Glowing, immune, 20 mg daily: “My Neurologist says this DMT is the reason I can still walk unaided.” — [r/MultipleSclerosis](https://www.reddit.com/r/MultipleSclerosis/comments/1irdcel/starting_copaxone_glatiramer_acetate_tomorrow_and/mdazsrl/)
- Glowing, immune: “12 years on Copaxone and no relapses. All MRIs showing no new issues as well.” — [r/MultipleSclerosis](https://www.reddit.com/r/MultipleSclerosis/comments/164uc24/how_effective_is_copaxone/jyb0mzl/)
- Positive, immune, 40 mg 3x/week: “I have now given myself shots for 5 years 3 times a week and haven't had any new lesions!” — [r/MultipleSclerosis](https://www.reddit.com/r/MultipleSclerosis/comments/fsoa5p/february_2020_i_celebrated_5yrs_no_new_lesions_on/)
- Positive, immune: “Been on copaxone for nearly 11 years,got my yearly MRI results afew months ago and there has been zero change so copaxone seems to be working well for me” — [r/MultipleSclerosis](https://www.reddit.com/r/MultipleSclerosis/comments/1czvgi2/people_on_copaxone_share_your_experiences/l5k1rhd/)
- Positive, immune: “I'd describe it as suddenly feeling like I had flu, felt cold all over and shaky, I went back to bed shivering and fell asleep then woke up 20-30 mins later and it had gone.” — [r/MultipleSclerosis](https://www.reddit.com/r/MultipleSclerosis/comments/1czvgi2/people_on_copaxone_share_your_experiences/l5j71hu/)

## Studies

- [Johnson et al. 1995: copolymer 1 phase III trial in relapsing-remitting MS](https://pubmed.ncbi.nlm.nih.gov/7617181/) (rct, n=251, 1995): 20 mg daily for two years cut the relapse rate 29% versus placebo (0.59 vs 0.84 a year); a transient systemic post-injection reaction hit 15.2% versus 3.2% on placebo.
- [Khan et al. 2013 (GALA): glatiramer acetate 40 mg three times weekly](https://pubmed.ncbi.nlm.nih.gov/23686821/) (rct, n=1404, 2013): 34% fewer confirmed relapses than placebo over 12 months and fewer enhancing (45%) and new T2 (35%) lesions; injection-site reactions in 35.5% versus 5%.
- [Wolinsky et al. 2007 (PROMiSe): glatiramer acetate in primary progressive MS](https://pubmed.ncbi.nlm.nih.gov/17262850/) (rct, n=943, 2007): Stopped early when an interim analysis found no effect on disability progression.
- [La Mantia et al. 2010: Cochrane review, glatiramer acetate for multiple sclerosis](https://www.cochrane.org/evidence/CD004678_use-glatiramer-acetate-copaxone-r-people-multiple-sclerosis) (meta-analysis, n=1589, 2010): Six RCTs; a slight reduction in relapse risk in relapsing-remitting MS, no effect on progression in either relapsing or progressive MS, frequent flushing, chest tightness and injection-site reactions.
- [Aharoni et al. 2008: demyelination arrest and remyelination induced by glatiramer acetate in EAE](https://pubmed.ncbi.nlm.nih.gov/18678887/) (animal, 2008): In mice with autoimmune encephalomyelitis, treatment reduced demyelination and showed signs of remyelination even when started after symptoms; this is the main basis for 'brain repair' claims, which have not been shown in patients.
- [FDA Drug Safety Communication (January 2025): boxed warning for anaphylaxis](https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-about-rare-serious-allergic-reaction-called-anaphylaxis-multiple-sclerosis) (observational, n=82, 2025): 82 worldwide anaphylaxis cases from 1996 to May 2024, 19 starting more than a year into treatment, all needing emergency care or hospitalisation; six died.

## Sources

- [Copaxone prescribing information (FDA label, revised January 2025, boxed warning)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020622s118s119lbl.pdf)
- [FDA Drug Safety Communication: boxed warning for anaphylaxis with glatiramer acetate (22 Jan 2025)](https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-about-rare-serious-allergic-reaction-called-anaphylaxis-multiple-sclerosis)
- [Cochrane 2010: glatiramer acetate for multiple sclerosis](https://doi.org/10.1002/14651858.cd004678.pub2)
- [Teva 2016: pregnancy contraindication removed from the European Copaxone label](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2016/Teva-Receives-Positive-Outcome-for-COPAXONE-Label-in-Europe/default.aspx)